20-Jan-10
Notice of Interest
more >>

14-Jan-10
New Year Progress Report on Verona Pharma plc
more >>

06-Jan-10
Application for admission of new Ordinary Shares
more >>
















Subscribe to our Email List



Verona Pharma plc is a life sciences company dedicated to the research, discovery and development of new therapeutic drugs for the treatment of allergic rhinitis (hay fever) and other chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), as well as chronic inflammatory diseases.

Verona Pharma currently has three potential drug treatments under development and continues to look for other possible drug development opportunities aimed at the respiratory and inflammatory diseases markets.

Verona Pharma is incorporated in the United Kingdom and has its principal office in central London. Verona Pharma is traded on the AIM stock exchange under the symbol VRP.

The information on this website is made available pursuant to AIM Rule 26. This website was last updated on 14 January 2010.